跳至主要内容
临床试验/NCT03942120
NCT03942120已完成不适用

Post-Marketing Surveillance for Crohn's Disease Patients Treated With STELARA

Janssen Korea, Ltd., Korea42 个研究点 分布在 1 个国家目标入组 685 人开始时间: 2019年4月8日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
685
试验地点
42
主要终点
Number of Participants with Adverse Events

研究概览

简要总结

The purpose of post-marketing surveillance (PMS) is to assess the safety and effectiveness of ustekinumab (Stelara) for Crohn's disease participants under real world clinical practice.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Participants who are administered with Stelara for the first time for the indication of Crohn's disease in accordance with the label
  • Participants must sign a participation agreement/informed consent form (ICF) allowing data collection and source data verification in accordance with local requirements

排除标准

  • Have contraindication to Stelara in accordance to the label

研究组 & 干预措施

Participants with Crohn's Disease

Participants that are diagnosed with Crohn's disease will be observed in this study who are being treated with ustekinumab under real world clinical practice. Only data available per clinical practice will be collected within this study.

干预措施: Ustekinumab (Drug)

结局指标

主要结局

Number of Participants with Adverse Events

时间窗: Approximately up to 3 years

An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.

Change from Baseline in Crohn's Disease Activity Index (CDAI) Score

时间窗: Baseline up to 3 years

CDAI is a scoring system to assess the symptoms of participants with Crohn's disease (CD). It consists of 8 different CD-related factors that are summed after adjustment with a weighting factor. These 8 variables are: extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug(s) and/or opiates, total number of liquid stools, abdominal pain/cramping, and general well-being. CDAI total score ranges from 0 to 900 and a decrease over time indicates improvement in disease activity.

Change from Baseline in C-reactive Protein (CRP) Concentration

时间窗: Baseline up to 3 years

Change from baseline in CRP concentration will be assessed.

Change from Baseline in Harvey-Bradshaw Index (HBI) Score

时间窗: Baseline up to 3 years

HBI is a shorter and simpler alternative version of CDAI which consists of five parameters that allow physicians to quickly categorize the severity of Crohn's disease and detect remission. The 5 parameters are: general well-being (0-4, where higher score means lower well-being), abdominal pain (0-3, higher score means more severe pain), number of liquid stools per day (score 1 per movement), abdominal mass (0=none, 1=dubious, 2=definite, 3=definite and tender), and complications (score 1 per item). Total score is the sum of individual parameters. The score ranges from a minimum score of 0 to no pre-specified maximum score as it depends on the number of liquid stools per day and number of complications, where higher scores indicate more severe disease and, score is presented as: less than (\<)5 (remission), 5-7 (mild disease), 8-16 (moderate disease), and greater than (\>)16 (severe disease).

Change from Baseline in Fecal Calprotectin Level

时间窗: Baseline up to 3 years

Change from baseline in fecal calprotectin levels will be assessed. Elevated calprotectin level in the stool indicates that inflammation is present in the intestine and the degree of elevation is associated with the severity of the inflammation.

Change from Baseline in Simple Endoscopic Score for Crohn's Disease (SES-CD)

时间窗: Baseline up to 3 years

SES-CD is a simplified endoscopic scoring system to evaluate Crohn's disease activity developed as an alternative to Crohn's disease endoscopic index of severity (CDEIS). It assesses the size of mucosal ulcers, the ulcerated surface, the endoscopic extension and the presence stenosis. Each endoscopic component is scored from 0 to 3 for each segment, and a total score is derived from the sum of all the component scores (range, 0 \[remission\] to 60 \[the most severe endoscopic activity\]).

Change from Baseline in Short Inflammatory Bowel Disease Questionnaire (SIBDQ) Score

时间窗: Baseline up to 3 years

SIBDQ is a simple, validated 10-item self-reported questionnaire for participants with inflammatory bowel disease to evaluate participant-reported outcomes in 4 domains- digestive symptoms (3 items), systemic symptoms (2 items), emotional disturbance (3 items), and social function (2 items). Participants rate each item on a 7-point Likert scale (1=all of the time; 2=most of the time; 3=a good bit of the time; 4=some of the time; 5=a little bit of the time; 6=hardly any of the time; 7=none of the time). Total score is calculated by adding the scores from each domain; the total score ranges from 10 to 70, where minimum score =10 (poor quality of life) and maximum score =70 (good quality of life).

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (42)

Loading locations...

相似试验